SEARCH

SEARCH BY CITATION

References

  • 1
    Resche-Rigon M, Azoulay E, Chevret S. Evaluating mortality in intensive care units: contribution of competing risks analyses. Crit Care 2006;10:103.
  • 2
    Glück T, Silver J, Epstein M, Cao P, Farber B, Goyert SM. Parameters influencing membrane CD14 expression and soluble CD14 levels in sepsis. Eur J Med Res 2001;6:3518.
  • 3
    Zhang DE, Hetherington CJ, Tan S et al. Sp1 is a critical factor for the monocytic specific expression of human CD14. J Biol Chem 1994;269:1142534.
  • 4
    LeVan TD, Bloom JW, Bailey TJ et al. A common single nucleotide polymorphism in the CD14 promoter decreases the affinity of Sp protein binding and enhances transcriptional activity. J Immunol 2001;167:583844.
  • 5
    D'Avila LC, Albarus MH, Franco CR et al. Effect of CD14 −260C>T polymorphism on the mortality of critically ill patients. Immunol Cell Biol 2006;84:3428.
    Direct Link:
  • 6
    Fallavena PRV, Borges TJ, Paskulin DD et al. The influences of CD14 -260C>T polymorphism on survival in ICU critically ill patients. Immunol Invest 2009;38:797811.
  • 7
    Barber RC, Chang LY, Arnoldo BD et al. Innate immunity SNPs are associated with risk for severe sepsis after burn injury. Clin Med Res 2006;4:2505.
  • 8
    Barber RC, Aragaki CC, Chang LY et al. CD14-159 C allele is associated with increased risk of mortality after burn injury. Shock 2007;27:2327.
  • 9
    Aguiar BB, Girardi I, Paskulin DD et al. CD14 expression in the first 24h of sepsis: effect of -260C>T CD14 SNP. Immunol Invest 2008;37:75269.
  • 10
    Vainas T, Stassen FR, Bruggeman CA et al. Synergistic effect of Toll-like receptor 4 and CD14 polymorphisms on the total atherosclerosis burden in patients with peripheral arterial disease. J Vasc Surg 2006;44:32632.
  • 11
    Takeuchi O, Hoshino K, Kawai T et al. Differential roles of TLR2 and TLR4 in recognition of gram-negative and gram-positive bacterial cell wall components. Immunity 1999;11:44351.
  • 12
    Poikonen K, Lajunen T, Silvennoinen-Kassinen S, Leinonen M, Saikku P. Effects of CD14, TLR2, TLR4, LPB, and IL-6 gene polymorphisms on Chlamydia pneumoniae growth in human macrophages in vitro. Scand J Immunol 2009;7:309.
  • 13
    Medzhitov R, Janeway CA Jr. Innate immunity: the virtues of a nonclonal system of recognition. Cell 1997;91:2958.
  • 14
    Arancibia SA, Beltran CJ, Aguirre IM et al. Toll-like receptors are key participants in innate immune responses. Biol Res 2007;40:97112.
  • 15
    Dobrovolskaia MA, Vogel SN. Toll receptors, CD14, and macrophage activation and deactivation by LPS. Microbes Infect 2002;4:90314.
  • 16
    Namath A, Patterson AJ. Genetic polymorphisms in sepsis. Crit Care Clin 2009;25:83556.
  • 17
    Teuffel O, Ethier MC, Beyene J, Sung L. Association between tumor necrosis factor-alpha promoter -308 A/G polymorphism and susceptibility to sepsis and sepsis mortality: a systematic review and meta-analysis. Crit Care Med 2010;38:27682.
  • 18
    Seitsonen SP, Onkamo P, Peng G et al. Multifactor effects and evidence of potential interaction between complement factor H Y402H and LOC387715 A69S in age-related macular degeneration. PLoS ONE 2008;3:e3833.
  • 19
    Gigante B, Bennet AM, Leander K, Vikström M, de Faire U. The interaction between coagulation factor 2 receptor and interleukin 6 haplotypes increases the risk of myocardial infarction in men. PLoS ONE 2010;5:e11300.
  • 20
    Salzano FM, Freire-Maia N. Problems in Human Biology. A Study of Brazilian Populations. Detroit: Wayne State University Press, 1970.
  • 21
    Parra FC, Amado RC, Lambertucci JR, Rocha J, Antunes CM, Pena SD. Color and genomic ancestry in Brazilians. Proc Natl Acad Sci U S A 2003;100:17782.
  • 22
    Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med 1985;13:81829.
  • 23
    Vincent JL, Ferreira FL. Multiple organ failure: Clinical syndrome. In: Evans TW, Fink MP, eds. Mechanisms of Organ Dysfunction in Critical Illness. Verlag Berlin Heidelberg: Intensive Care Medicine Springer 2002: 394403.
  • 24
    Bone RC, Balk RA, Cerra FB et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. Chest: American College of Chest Physicians/Society of Critical, 1992: 101:164455.
  • 25
    Lahiri DK, Nurnberger JI Jr. A rapid non-enzymatic method for the preparation of HMW DNA from blood for RFLP studies. Nucl Acids Res 1991;19:5444.
  • 26
    Thurow HS, Sarturi CR, Fallavena PR et al. Very low frequencies of Toll-like receptor 2 supposed-2029T and 2258A (RS5743708) mutant alleles in southern Brazilian critically ill patients: would it be a lack of worldwide-accepted clinical applications of Toll-like receptor 2 variants? Genet Test Mol Biomarkers 2010;14:40519.
  • 27
    Arbour NC, Lorenz E, Schutte BC et al. TLR4 mutations are associated with endotoxin hyporesponsiveness in humans. Nat Genet 2000;25:18791.
  • 28
    Moraes JFD, Souza VBA. Factors associated with the successful aging of the socially-active elderly in the metropolitan region of Porto Alegre. Rev Bras Psiquiatr 2005;27:3028.
  • 29
    Ryan MH, Gardner HR, Barber RC. Pathway genetic load allows simultaneous evaluation of multiple genetic associations. Burns 2010;36:78792.
  • 30
    Liu J, Song B, Bai X et al. Association of genetic polymorphisms in the interleukin-10 promoter with risk of prostate cancer in Chinese. BMC Cancer 2010;10:456.
  • 31
    Heesen M, Bloemeke B, Schade U, Obertacke U, Majetschak M. The -260 C–>T promoter polymorphism of the lipopolysaccharide receptor CD14 and severe sepsis in trauma patients. Intensive Care Med 2002;28:11613.
  • 32
    Koenig W, Khuseyinova N, Hoffmann MM et al. CD14 C(-260)–>T polymorphism, plasma levels of the soluble endotoxin receptor CD14, their association with chronic infections and risk of stable coronary artery disease. J Am Coll Cardiol 2002;40:3442.
  • 33
    Karhukorpi J, Yan Y, Niemela S et al. Effect of CD14 promoter polymorphism and H. pylori infection and its clinical outcomes on circulating CD14. Clin Exp Immunol 2002;128:32632.
  • 34
    Lin J, Yao YM, Yu Y et al. Effects of CD14-159 C/T polymorphism on CD14 expression and the balance between proinflammatory and anti-inflammatory cytokines in whole blood culture. Shock 2007;28:14853.
  • 35
    Locksley RM, Killeen N, Lenardo MJ. The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell 2001;104:487501.
  • 36
    Schottelius AJ, Moldawer LL, Dinarello CA, Asadullah K, Sterry W, Edwards CK. Biology of tumor necrosis factor-alpha – implications for psoriasis. Exp Dermatol 2004;13:193222.
  • 37
    Wood LJ, Nail LM, Gilster A, Winters KA. Cancer chemotherapy-related symptoms: evidence to suggest a role for proinflammatory cytokines. Oncol Nurs Forum 2006;33:53542.
  • 38
    Kroeger KM, Carville KS, Abraham LJ. The -308 tumor necrosis factor-α promoter polymorphism effects transcription. Mol Immunol 1997;34:3919.
  • 39
    Wilson AG, Symons JA, McDowell TL, McDevitt HO, Duff GW. Effects of a polymorphism in the human tumor necrosis factor-α promoter on transcriptional activation. Immunol 1997;94:31959.
  • 40
    Hajeer AH, Hutchinson IV. Influence of TNFalpha gene polymorphisms on TNFalpha production and disease. Hum Immunol 2001;62:11919.
  • 41
    Ioannidis JPA, Trikalinos TA, Ntzani EE, Contopoulos-Ioannidis DG. Genetic associations in large versus small studies: an empirical assessment. Lancet 2003;361:56771.
  • 42
    Brunialti MK, Martins PS, Barbosa de Carvalho H, Machado FR, Barbosa LM, Salomao R. TLR2, TLR4, CD14, CD11B, and CD11C expressions on monocytes surface and cytokine production in patients with sepsis, severe sepsis, and septic shock. Shock 2006;25:3517.
  • 43
    Nyquist PA, Winkler CA, McKenzie LM, Yanek LR, Becker LC, Becker DM. Single nucleotide polymorphisms in monocyte chemoattractant protein-1 and its receptor act synergistically to increase the risk of carotid atherosclerosis. Cerebrovasc Dis 2009;28:12430.